Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954595 | 0.91 | IL1B (0.35) | MAP3K12GAANR3C2TRPV1TLR9 | |
| SCHEMBL19954593 | 0.88 | GAA (0.35) | POLBGAANR3C2TRPV1 | |
| SCHEMBL19954591 | 0.86 | MAPK1 (0.35) | MAP3K12GAANR3C2TLR9TLR8 | |
| SCHEMBL19954655 | 0.85 | GAA (0.36) | GAANR3C2TRPV1TLR9TLR8 | |
| SCHEMBL19954579 | 0.83 | NR3C2 (0.36) | GAANR3C2TRPV1TLR9TLR8 | |
| SCHEMBL19954580 | 0.83 | BTK (0.36) | MAP3K12TLR9TLR8TLR7 | |
| SCHEMBL19954637 | 0.82 | ALDH1A1 (0.34) | MAP3K12NR3C2 | |
| SCHEMBL19954664 | 0.81 | MAPK1 (0.39) | NR3C2TRPV1TLR9TLR8TLR7 | |
| SCHEMBL19954553 | 0.80 | NR3C2 (0.40) | TSHRMAP3K12GAANR3C2TRPV1 | |
| SCHEMBL19954576 | 0.80 | HTR2A (0.38) | POLBCYP2C9TSHRGAANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080087-B1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2019-05-22 | — | — | EP | disclosed |